Vaccine World China 2014

Top Quote The ONLY Vaccine Development and Manufacturing focused gathering in China! Vaccine World Summit is one of the most sought after vaccine industrial gathering for developing country manufacturers, which happens every year in India, China, Korea and Turkey. End Quote
  • (1888PressRelease) August 06, 2014 - Singapore - China's Vaccine Manufactures looking for a slice of the Global Pie. China's key vaccine players will be gathering to discuss the latest lifesaving vaccines, examine the latest vaccine manufacturing practices and share the newest product developments at the 2nd Annual Vaccine World China 2014 in Holiday Inn Hangzhou City Centre, Hangzhou, China, on 4 to 5 September 2014.

    As China's socio-economic landscape continues to change, the healthcare industry looks certain to follow suit. Immunization rates for vaccines included in the Expanded Programme of Immunisation (EPI) have achieved a 99% with the Chinese Government looking to increase the panel of vaccines required for childhood immunization. These vaccines include inactivated polio vaccine (IPV), which is at present not produced by Chinese manufacturers at all. While IPV has become available since September 2009 due to importation, but the supply is still largely limited. In 2012, state-owned enterprises took up 81.5% of the vaccine lot release quantity in the EPI vaccine market. However, improved access to China's vaccine market coupled with extra funding gave private companies and multinational corporations greater incentives to join in the race to produce more EPI vaccines.

    In addition to increased government funding, Chinese manufactures are producing more vaccines to meet growing domestic demand. With Chengdu Institute of Biological Products receiving China's first WHO pre-qualifications, many companies are expected to follow suit. "Since the prequalification of Japanese encephalitis (JE) vaccine from China, we can expect more and more enterprises taking part in obtaining prequalification and introducing more vaccines to the foreign countries in order to meet the un-met demands worldwide," Wu Ke, CEO of BRAVOBIO mentions in China's Perspectives: An Interview with our Advisory Board.

    In the same interview, Dr. Li Jian Ping, CEO of Kanwax Biopharmaceuticals observes, "I believe that there are a number of companies that will follow this trend to obtain prequalification of their vaccine products such as flu vaccine, DTap and etc. for exporting. The question is whether every company will try to get WHO prequalification status for all their vaccine products. We have to think if the ratio of cost versus profit makes WHO prequalification worth the investment."

    Both Dr Wu Ke and Li Jian Ping will be attending the 2nd Annual Vaccine World China 2014 this September in Hangzhou. To engage in more first-hand industry dialogue and unparalleled insights into the projects, register now and meet these experts and more at Vaccine World China 2014 personally.

    Partnerships between Chinese manufacturers and foreign biotechnology firms have also been on rise. Companies such as Beijing Minhai have recently partnered FIT Biotech to co-produce a tuberculosis (TB) vaccine platform using FIT Biotech's gene transfer unit (GTU) technology. More insights on this trend can be gained at September's Vaccine World China 2014 as Dr Wu Ke, CEO of BRAVOBIO discusses how to maximize and leverage on the strength of companies within and outside of China for vaccine innovations.

    In response to China's increasing role in the vaccine industry, IMAPAC intends to maximize China's potential in the healthcare industry by bringing together key manufactures and policymakers under one roof in Hangzhou this September. Download the event brochure here for more information.

    Vaccine World China 2014 will be gathering Vaccine R&D and manufacturing leaders to discuss and debate the latest vaccine manufacturing practices and share newest product developments. The gathering will feature insights and presentations by key Chinese players in the vaccine market such as, Baiming Biotechnology Co Ltd, North China Pharmaceutical Group Co., Wuhan Institute of Biological Products, National Vaccine and Serum Institute and many more.

    International key players such as Curevac, MedImmune, Eurocine Vaccines AB etc., will also be contributing their thoughts and views of the Vaccine market in China. With over 30 hours of networking, more than 20 presentations, and over a 100 representatives, Vaccine World China 2014 promises to be the year's most sought after vaccine industrial gathering in China!

    About IMAPAC Pte Ltd
    IMAPAC is a social enterprise that is on an unrelenting mission to strive and make a difference to businesses of today. We believe businesses are not only meant to do well, but also to do well. We want you to find business opportunities at our conferences as well something good to aim for. IMAPAC's conferences are when you join other organizations such as governments, NGOs, businesses, academics and other stakeholders who standing up collectively to make a difference, to attest to the fact that businesses can and do make a positive impact to the world we are living in.

    Jason Tan
    jason.tan ( @ ) imapac dot com
    100 Beach Road
    #16-0/13 Shaw Tower
    Singapore 189702

  • FB Icon Twitter Icon In-Icon
Contact Information
  • Cecilia Wong
  • Imapac
  • 298 Tiong Bahru Road #20-04 Central Plaza
  • 168730
  • Voice: 65 6493 1871
  • Visit our Site